Obesity Drug – Talk Bio

Lilly Prepares Amylin-Based Obesity Drug Eloralintide for Phase III After Strong Weight Loss Results

3 weeks ago talkbio0Tagged Agonist, Amylin, Clinical Development, Eli, Eli Lilly, Eloralintide, Obesity Drug, Phase 3 Clinical Trials, Weight Loss

Eli Lilly; eloralintide; amylin agonist; obesity drug; Phase III trial; weight loss; clinical development

Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline

1 month ago talkbio0Tagged liver enzyme elevation, Metabolic Diseases, Myeloid Leukemia, Chronic, Neoplasms, Obesity Drug, Phase 2 trial, Product containing glucagon-like peptide 1 receptor agonist (product), TERN-601, TERN-701, Terns, Weight Loss

Terns Pharmaceuticals; TERN-601; obesity drug; GLP-1 receptor agonist; Phase 2 trial; weight loss; liver enzyme elevation; oncology; TERN-701; chronic myeloid leukemia (CML); metabolic disease

Kailera Raises $600 Million to Launch Global Phase III Program for Obesity Drug

2 months ago talkbio0Tagged Bain Capital, clinical pipeline, Funding, GLP-1/GIP Dual Agonist, Kailera, Obesity Drug, Phase 3 Clinical Trials, Series B financing, weight loss therapy

Kailera; obesity drug; Phase III clinical trial; KAI-9531; GLP-1/GIP dual agonist; Series B financing; Bain Capital; weight loss therapy; clinical pipeline; biotech funding